eli lilly's tirzepatide is the leader in weight loss sector Lilly Trims Price of Popular Weight-Loss Drug on Its Site a Month After Trump Deal FDA approves Lilly's Zepbound (tirzepatide)

Among these studies, one constituted an RCT, while the other was a cohort study

[DOI] [PubMed] [Google Scholar] 16.Riley RD, Higgins JPT, Deeks JJ

The change from baseline in HbA1c at week 40 corresponds to the primary endpoint in SURPASS2 and SUSTAIN FORTE

Using a linear trimming estimator in the trim and fill model, one study was attributed to the left side of the funnel plot

In a sector where innovation and access are everything, Eli Lilly looks like a bargain for investors seeking durable growth in one of healthcares most promising markets

Instead, they highlight the need for close monitoring of high-risk patients